TP53 and neoplasm: Consequently, we narrowed our focus to the TERTp+/TP53+ group to perform pathway enrichment analysis and used multiplex immunofluorescence (mIF) to evaluate the impact of co‐mutation on the tumor immune microenvironment (TIME).